EUCTR2013-003976-11-DK进行中（未招募）1 期
Effects of S-1 and capecitabine in combination with oxaliplatin on the coronary artery blood flow in patients metastatic gastrointestinal tract adenocarcinoma - Fluo Heart
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Has given written informed consent.
- •2.Is >18 years of age.
- •3.Has advanced or metastatic gastrointestinal tract adenocarcinoma.
- •4.No previous cancer chemotherapy for cancer.
- •5.Measurable or evaluable lesions according to RECIST v1.1 criteria.
- •6.Is able to take medications orally.
- •7.Has ECOG performance status 0 or 1 on Cycle 1, Day 1 (see Appendix A).
- •8.Has a life expectancy of at least 3 months.
- •9.Serum troponin T or I and creatine phosphokinase (CPK)-MB values < upper limit of normal (ULN) for the institution.
- •10.Has adequate organ function as defined by the following criteria:
- •a.Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) =2 x ULN; if liver function abnormalities are due to underlying liver metastasis, AST (SGOT) and ALT (SGPT) =6 x ULN.
- •b.Total serum bilirubin of =1.5 x ULN.
- •c.Absolute neutrophil count of =1,500/mm3 (i.e., =1.5 x 109/L by International Units [IU])
- •d.Platelet count =100,000/mm3 (IU: =100 x 109/L) (excluding measurements obtained within 7 days after transfusion).
- •e.Hemoglobin value of =11.0 g/dL.
- •f.Creatinine < 1.5 x ULN. I creatinine clearance is measured, this should be =60 mL/min based on calculated creatinine clearance (Cockcroft-Gault13 formula, see Appendix D) or 24-hour urine collection.
- •g.Is willing and able to comply with scheduled visits, treatment plan, lab tests and other study procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •1.Has had treatment with any of the following within the specified time frame prior to study drug administration:
- •a.Cancer considered operable without prior chemotherapy.
- •b.Prior chemotherapy to cancer.
- •c.Previous therapy with fluoropyrimidines or anthracyclines for any indication.
- •d.Inability to swallow tablets.
- •e.Patients with known DPD deficiency.
- •f.Any investigational agent received either concurrently or within the last4 weeks.
- •g.Current enrollment in another interventional clinical study.
- •2.Has a serious illness or medical condition(s) including, but not limited to, the following:
- •a.Known brain metastasis or leptomeningeal metastasis.
- •b.Patient with a history of myocardial infarction within the last 6 months, or with a history of coronary surgery or stenting, severe/unstable angina, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack, pulmonary embolism, or deep vein thrombosis within the last 12 months.
- •c.Symptomatic congestive heart failure (New York Heart Association [NYHA] class III or IV (see Appendix E).
- •d.Ongoing cardiac dysrhythmias (=Grade 2), atrial fibrillation (any grade), or prolongation of QTc interval (>450 msec for males; >470 msec for females).
- •e.Patients with any cardiac disease that requires regular medication (medication for vascular diseases such as hypertension is allowed).
- •f.Hypertensive crisis or severe hypertension that is not controlled.
- •g.Known acute systemic infection.
- •h.Chronic nausea, vomiting, or diarrhea considered to be clinically significant in the opinion of the Investigator.
- •i.=Grade 1 peripheral neuropathy.
- •j.Recent hemoptysis, coagulopathy and other bleeding disorders considered by the Investigator to be clinically significant.
- •k.Known nephrotic syndrome (proteinuria >2 g/24 hours).
- •l.Known clinically significant interstitial lung disease or pulmonary fibrosis.
- •m.Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
- •n.Organ allografts with immunosuppressive therapy required.
- •o.Major surgery within 3 weeks prior to study treatment start, or lack of complete recovery from the effects of surgery.
- •p.Clinically significant malabsorption syndrome
- •q.Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the patient inappropriate for entry into this study.
- •3.Is receiving concomitant treatment with short-acting nitroglycerins, or one or more of the following drugs that may interact with S-1or capecitabine:
- •a.Sorivudine, brivudine, uracil, eniluracil, cimetidine, folinate/folinic acid, and dipyridamole (may enhance S-1or capecitabine activity).
- •b.Nitroimidazoles, including metronidazole and misonidazole (may enhance S-1 activity)
- •c.Clozapine (may increase risk and severity of hematologic toxicity)
- •d.Allopurinol (may diminish S-1 activity).
- •e.Phenytoin (S-1 may enhance phenytoin activity).
- •f.Flucytosine, a fluorinated pyrimidine antifungal agent (may enhance S-1 activity).
- •4.Is a pregnant or lactating female.
- •5.Female patients of childbearing potential must have negative pregnancy test before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and f
研究者
相似试验
进行中（未招募）
1 期
Effect of two cancer drugs (S-1 and capecitabine) on the blood circulation of the heart.Metastatic gastrointestinal tract adenocarcinomaEUCTR2013-003976-11-FIHelsinki University Central Hospital40
已完成
3 期
S-1 versus capecitabine in the first line treatment of metastatic colorectal cancer patients, the SALTO randomised phase III study of the Dutch Colorectal Cancer Group. A safety evaluation of oral fluoropyrimidines.Bowel CancerColorectalcancer10017991NL-OMON41674Dutch Colorectal Cancer Group160
进行中（未招募）
不适用
S-1 (Teysuno) versus capecitabine with or without bevacizumab, as first line treatment in patients with metastazised bowel cancer. A study of the Duthch colorectal Cancer Group.EUCTR2013-002147-28-NLDutch Colorectal Cancer Group
已完成
不适用
Phase I/II Study of Capecitabine in Combination with Peginterferon Alfa-2a for Patients with Advanced Hepatocellular CarcinomaHepatocellular CarcinomaJPRN-UMIN000005697Chiba University Hospital42
进行中（未招募）
不适用
A phase II study of Capecitabine in combination with Cisplatin in advanced head and neck Cancer - NDAdvanced or metastatic head and neck cancerLevel: HLTClassification code 10024530EUCTR2006-003775-13-ITOSPEDALE ONCOLOGICO DI BARI43